These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9306129)

  • 1. Fibrinopeptide A, prothrombin fragment 1 + 2, thrombin-antithrombin complex and D dimer before and after injection of a nonionic contrast medium (iohexol).
    Sorano GG; Paoletti P; Casciu G; Mameli G; Marongiu F
    Haemostasis; 1997; 27(3):125-30. PubMed ID: 9306129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAT, F1 + 2, and D-dimer levels in patients after coronary angiography with nonionic or ionic contrast media or after cardiac catheterization.
    Biancardi M; Cimminiello C; Toschi V; Schiavina G; Regalia F; Casolo F; Bonfardeci G
    Semin Thromb Hemost; 1996; 22 Suppl 1():61-5. PubMed ID: 8807731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2.
    Boisclair MD; Lane DA; Philippou H; Sheikh S; Hunt B
    Thromb Haemost; 1993 Aug; 70(2):253-8. PubMed ID: 8236130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of coagulation and fibrinolysis in portal blood from patients with and without gastric malignancy.
    Rahr HB; Sørensen JV; Larsen JF; Jensen FS; Bredahl C
    Scand J Gastroenterol; 1994 Jun; 29(6):516-21. PubMed ID: 8079109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.
    Scharfstein JS; Abendschein DR; Eisenberg PR; George D; Cannon CP; Becker RC; Sobel B; Cupples LA; Braunwald E; Loscalzo J
    Am J Cardiol; 1996 Sep; 78(5):503-10. PubMed ID: 8806332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin-antithrombin III complex and D-Dimer levels in patients affected by proximal deep vein thrombosis.
    Elias A; Bonfils S; Daoud-Elias M; Gauthier B; Sié P; Boccalon H; Boneu B
    Thromb Haemost; 1993 Apr; 69(4):302-5. PubMed ID: 8497840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical evidence for a relative lack of inhibition of thrombin formation by nonionic contrast media.
    Mamon JF; Hoppensteadt D; Fareed J; Moncada R
    Radiology; 1991 May; 179(2):399-402. PubMed ID: 2014281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.
    Garcia-Avello A; Garcia-Frade LJ; Gandarias C; Ocaña J; Cancelas JA; Lasso M
    Thromb Res; 1994 Jan; 73(2):109-15. PubMed ID: 8171409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers.
    Slaughter TF; LeBleu TH; Douglas JM; Leslie JB; Parker JK; Greenberg CS
    Anesthesiology; 1994 Mar; 80(3):520-6. PubMed ID: 8141448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
    Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1998 Mar; 79(3):509-10. PubMed ID: 9531030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
    Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential thrombogenic action of a nonionic radiographic contrast medium used during coronary angiography is offset by heparin during coronary angioplasty.
    Mukherjee M; Scully MF; Thomas M; Jewitt D; Kakkar VV
    Thromb Haemost; 1996 Nov; 76(5):679-81. PubMed ID: 8950772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble, thrombin-related material in arterial thrombi and plasma studied during catheter-directed intra-arterial thrombolysis.
    Sandbaek G; Bjørnsen S; Brosstad F
    Blood Coagul Fibrinolysis; 1999 Mar; 10(2):87-91. PubMed ID: 10192657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation.
    Gando S; Nanzaki S; Sasaki S; Kemmotsu O
    Thromb Haemost; 1998 Jun; 79(6):1111-5. PubMed ID: 9657433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years.
    Cadroy Y; Pierrejean D; Fontan B; Sié P; Boneu B
    Nouv Rev Fr Hematol (1978); 1992; 34(1):43-6. PubMed ID: 1523099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin formation and degradation in patients with arteriosclerotic disease.
    Herren T; Stricker H; Haeberli A; Do DD; Straub PW
    Circulation; 1994 Dec; 90(6):2679-86. PubMed ID: 7994808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes.
    Kario K; Matsuo T; Kodama K; Matsuo M
    Thromb Res; 1992 Jun; 66(5):509-15. PubMed ID: 1523607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis.
    Giannitsis E; Siemens HJ; Mitusch R; Tettenborn I; Wiegand U; Schmücker G; Sheikhzadeh A; Stierle U
    Int J Cardiol; 1999 Mar; 68(3):269-74. PubMed ID: 10213277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation.
    Takahashi H; Wada K; Niwano H; Shibata A
    Blood Coagul Fibrinolysis; 1992 Dec; 3(6):813-8. PubMed ID: 1336986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.